Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000932:Antiemetics / Q000494:pharmacology*; D000077608:Aprepitant; D019540:Area Under Curve; D001189:Aryl Hydrocarbon Hydroxylases / Q000096:biosynthesis / Q000378:metabolism; D065729:Cytochrome P-450 CYP2C9; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000096:biosynthesis / Q000378:metabolism; D004311:Double-Blind Method; D004790:Enzyme Induction; D005260:Female; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008874:Midazolam / Q000378:metabolism / Q000494:pharmacology; D009025:Morpholines / Q000494:pharmacology*; D064729:Neurokinin-1 Receptor Antagonists; D014044:Tolbutamide / Q000378:metabolism / Q000494:pharmacology
D000932:Antiemetics; D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D000077608:Aprepitant; D003577:Cytochrome P-450 Enzyme System; D014044:Tolbutamide; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D008874:Midazolam